Megadin (Tablets) Instructions for Use

Marketing Authorization Holder

Mecom Saglik Urunleri, San. ve Tic. A.S. (Turkey)

Manufactured By

Abdi Ibrahim Ilac Sanayi ve Tic., A.S. (Turkey)

ATC Code

A11AA03 (Multivitamins and other minerals, including their combinations)

Dosage Form

Megadin

Coated tablets: 30 pcs.

Dosage Form, Packaging, and Composition

Coated tablets brown in color, round, biconvex.

Excipients: croscarmellose sodium (acdisol), D-mannitol, talc, polyvinylpyrrolidone K-30, microcrystalline cellulose PH 102, magnesium stearate, lactose, isopropyl alcohol.

Coating composition Opadry YS-1-7006 clear, ariavit brown, opalux brown, water.

10 pcs. – blisters (3) – cardboard packs.

Clinical-Pharmacological Group

Multivitamins with macro- and microelements

Pharmacotherapeutic Group

Multivitamin agent + multimineral

Pharmacological Action

Megadin is a combination of vitamins and minerals.

Vitamin A (Retinol): is a fat-soluble vitamin. Vitamin A deficiency leads to keratomalacia, xerophthalmia, and night blindness.

Vitamin E, due to its antioxidant action, protects cells from damage by free radicals.

Vitamin C is involved in tissue regeneration and collagen formation.

The B complex of vitamins is involved in the conversion of carbohydrates, protein, and fats.

Vitamin D ensures normal development of bones and teeth and regulates calcium utilization in the body.

Nicotinamide and Biotin are involved in various biochemical reactions.

Phosphate and Calcium are necessary for bone mineralization.

Iron and Copper are involved in the process of hematopoiesis, Zinc, Molybdenum, Magnesium, and Manganese are essential elements.

Indications

• Treatment of vitamin and mineral deficiency during convalescence after prolonged illnesses, in the pre- and postoperative period;
• In cases of malabsorption due to gastrointestinal diseases.

ICD codes

Dosage Regimen

Take one tablet orally once daily.

Administer the tablet during breakfast to enhance absorption and minimize potential gastrointestinal discomfort.

Swallow the tablet whole with a full glass of water; do not crush or chew.

The duration of treatment is determined by the physician based on the patient’s clinical condition and nutritional status.

Do not exceed the recommended daily dose.

Concurrent use with other vitamin or mineral supplements is not recommended without medical supervision due to the risk of hypervitaminosis or exceeding safe intake levels for certain minerals.

In patients with malabsorption syndromes, the therapeutic response should be monitored clinically.

Discontinue use and consult a physician if signs of hypersensitivity or other adverse reactions occur.

Adverse Reactions

Allergic reactions are possible. In high doses and with prolonged use, reactions such as allergic rash and ulceration of mucous membranes are possible.

Contraindications

• Hypervitaminosis A or D;
• Hypercalcemia or hypercalciuria;
• Pregnancy;
• Hypersensitivity to the components of the drug.

Use in Pregnancy and Lactation

Contraindicated during pregnancy.

Special Precautions

Megadin should be used in the recommended doses. In high doses, Megadin can cause hypervitaminosis.

Megadin should not be used simultaneously with other medicines containing vitamins and minerals without a doctor’s prescription.

Overdose

It must be emphasized that Megadin, in the doses recommended in the leaflet, does not cause symptoms of overdose or poisoning. Since Megadin contains fat-soluble vitamins A and D, signs of acute or chronic overdose may develop after a single high dose or with prolonged use.

Symptoms signs of vitamin A overdose include headache, dizziness, irritability, confusion, loss of appetite, vomiting, diarrhea, dry skin, and visual disturbances. The main signs of vitamin D overdose are nausea, vomiting, constipation, headache, dizziness, drowsiness, and deposition of calcium in internal organs (kidneys).

Treatment: in case of overdose, it is recommended to discontinue this medicine and carry out symptomatic treatment.

Drug Interactions

Do not use simultaneously with tetracyclines due to possible undesirable interaction.

If tetracyclines are indicated during the use of Megadin, the interval between taking these two medicines should be approximately 2 hours.

Storage Conditions

Store the drug at a temperature not exceeding 25°C (77°F), in a dry place. Keep out of reach of children.

Shelf Life

Shelf life – 2 years. Do not use after the date indicated on the packaging.

Dispensing Status

The drug is approved for use as an over-the-counter product.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.